In this review, Pistilli et al. examine persistent challenges in antibody-drug conjugate (ADC) development, including patient selection, biomarker validation, and preclinical modeling. Integrating emerging insights into tumor biology, resistance, and microenvironmental effects, the authors propose reframing ADCs as tumor-ecosystem-targeting therapies and outline paths to embed ADCs within precision oncology.
